- Home
- JAZZ vs ONON Comparison
JAZZ vs ONON Comparison
Compare JAZZ & ONON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | JAZZ | ONON |
|---|---|---|
| Founded | 2003 | 2010 |
| Country | Ireland | Switzerland |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Shoe Manufacturing |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.4B | 12.0B |
| IPO Year | 2007 | 2021 |
Fundamental Metrics
Financial Performance| Metric | JAZZ | ONON |
|---|---|---|
| Price | $207.36 | $34.35 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 14 | 20 |
| Target Price | ★ $217.57 | $60.15 |
| AVG Volume (30 Days) | 814.8K | ★ 5.1M |
| Earning Date | 05-05-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,618,693,000.00 | N/A |
| Revenue This Year | $6.22 | $19.58 |
| Revenue Next Year | $7.68 | $19.98 |
| P/E Ratio | ★ N/A | $56.05 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $105.00 | $31.41 |
| 52 Week High | $208.15 | $61.29 |
Technical Indicators
Market Signals| Indicator | JAZZ | ONON |
|---|---|---|
| Relative Strength Index (RSI) | 63.55 | 40.32 |
| Support Level | $194.77 | $31.41 |
| Resistance Level | $207.48 | $44.10 |
| Average True Range (ATR) | 5.04 | 1.18 |
| MACD | -0.02 | 0.08 |
| Stochastic Oscillator | 94.06 | 4.44 |
Price Performance
Historical ComparisonAbout JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
About ONON On Holding AG
Founded in Switzerland in 2010, sportswear firm On Holding generates 93% of its sales from athletic shoes. The brand is best known for its running shoes and its distinctive CloudTec soles. On also produces athletic apparel (6% of sales) and accessories (1%). The firm's merchandise is available in more than 80 countries and is sold through both wholesale (58% of sales) and company-owned channels (42%). In 2025, On generated 58% of its sales in North America, 25% in Europe, the Middle East, and Africa, and 17% in the Asia-Pacific region.